Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Retinitis Pigmentosa Market to Grow Rapidly at a CAGR of 16.8% by 2034 | DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

02 Apr, 2024, 21:31 GMT

Share this article

Share toX

Share this article

Share toX

The retinitis pigmentosa market is propelled forward by advancements in gene therapy and innovative treatment modalities, offering promising prospects for slowing down the progression of this degenerative eye disease. Additionally, increasing research investments, growing awareness, and collaborative efforts among pharmaceutical companies contribute to the market's momentum, fostering a more optimistic landscape for patients and potential therapeutic breakthroughs.

LAS VEGAS, April 2, 2024 /PRNewswire/ -- DelveInsight's Retinitis Pigmentosa Market Insights report includes a comprehensive understanding of current treatment practices, retinitis pigmentosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Retinitis Pigmentosa Market Report

  • According to DelveInsight's analysis, the market size for retinitis pigmentosa reached USD 500 million in 2023 across the 7MM and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall prevalent population of retinitis pigmentosa in the 7MM was reported as 274K in 2023. 
  • Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with 186,897 cases in 2023.
  • Currently, LUXTURNA is the only approved therapy for retinitis pigmentosa and is only authorized for the treatment of a small subpopulation of patients that have the RPE65 mutation. 
  • From the drugs currently under development for the treatment of retinitis pigmentosa, several different class can be highlighted: cell therapies, gene therapies, optogenetic gene therapies, oligonucleotides (e.g. oligonucleotides, antisense oligonucleotides, and antisense ribonucleic acid interference (RNAi) oligonucleotides), antibodies, peptides, recombinant proteins and peptides, synthetic peptides, and small molecules.
  • Out of all the potential therapies, market size of gene therapies contributes more than 70%, whereas small molecules and oligonucleotide contributes roughly 21% among overall revenue in 2034
  • There are development of Gene and cell therapies with diverse targets like RHO, USH2A, and RPGR. Apart from cell and conventional form of gene therapies, Optogenetics also presents an innovative gene therapy overcoming the limitations of traditional approaches. There are several companies that have advanced optogenetic retinal gene therapies into clinical trials including, GenSight Biologics (GS030), Bionic Sight (BS01), and Nanoscope Therapeutics (MCO-010) Whereas jCyte's jCell is one of the leading cell therapies currently in Phase IIb stage of development.
  • Leading retinitis pigmentosa companies such as Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, Aldeyra Therapeutics, and others are developing novel retinitis pigmentosa drugs that can be available in the retinitis pigmentosa market in the coming years.
  • Other promising retinitis pigmentosa therapies in the pipeline include Botaretigene sparoparvovec, AGTC-501, GS030, 4D 125, CTx PDE6B, OCU 400, EA-2353, Ultevursen, ADX 2191, and others.

Discover which therapies are expected to grab the major retinitis pigmentosa market share @ Retinitis Pigmentosa Market Report

Retinitis Pigmentosa Overview

Retinitis pigmentosa denotes a collection of hereditary retinal disorders that result in the degeneration of the retina and eventual blindness. The condition is marked by the gradual deterioration of both rod and cone photoreceptors, leading to night blindness and progressing visual field impairments. Subsequently, there is a gradual deterioration in central vision during daylight as a result of the diminished function of the less-sensitive cone photoreceptors. Often associated with genetic mutations, more than 44 genes have been identified in connection with retinitis pigmentosa. Inheritance patterns include recessive, dominant, or X-linked, and approximately 50% of cases involve unidentified mutations. The suspicion of retinitis pigmentosa arises in individuals with impaired night vision or a family history of the disorder. Retinitis pigmentosa diagnosis relies on the documentation of rod dysfunction, assessed through dark adaptation or electroretinogram, as well as the progressive decline in photoreceptor function, peripheral vision loss, and bilateral eye involvement. Ocular examination typically reveals preserved visual acuity until the advanced stages of the disease and diminished visual fields.

Retinitis Pigmentosa Epidemiology Segmentation

Among the 7MM, the total number of prevalent cases of retinitis pigmentosa in the US were ~113K in 2023.

In the 7MM, XLRP accounted for ~15% of the nonsyndromic retinitis pigmentosa.

Nonsyndromic retinitis pigmentosa is more prevalent than syndromic retinitis pigmentosa with ~65% cases of total retinitis pigmentosa.

The retinitis pigmentosa market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Retinitis Pigmentosa Diagnosed Prevalent Population
  • Retinitis Pigmentosa Gender-Specific Diagnosed Prevalence
  • Retinitis Pigmentosa Type-Specific Diagnosed Prevalence 
  • Sub-Type Specific Diagnosed Prevalence of Syndromic and Systemic Retinitis Pigmentosa
  • Sub-Type Specific Diagnosed Prevalence of Non-Syndromic Retinitis Pigmentosa

Retinitis Pigmentosa Treatment Market 

Existing therapies for retinitis pigmentosa treatment are constrained, but several advancements are on the brink of entering the therapeutic landscape. According to randomized clinical trials involving vitamins and supplements, the primary widely endorsed intervention is supplementing with high doses of vitamin A palmitate and fish oil, while concurrently avoiding vitamin E. However, these modifications merely serve to postpone degeneration. The accessibility of the retina to relatively safe surgical procedures, coupled with the immune privilege of the eye, positions retinal diseases as an optimal context for deploying cutting-edge approaches like gene therapy and stem cell therapy. These innovative methods hold promise in yielding effective treatments for certain forms of retinitis pigmentosa.

Due to the numerous complications, diverse forms, and varying stages associated with retinitis pigmentosa, treatment approaches are now customized based on the specific types of retinitis pigmentosa and their inheritance patterns. In Japan, however, there is a notable absence of standardized, evidence-based, and comprehensive curative treatments for retinitis pigmentosa. Nevertheless, there is optimism as several novel treatments are currently in clinical development, aiming to decelerate or potentially reverse the degeneration of the retina caused by the loss of photoreceptors.

In contrast to the United States, EU-4, and the UK, Japan has experienced numerous therapy failures in the final stages of retinitis pigmentosa treatment development. Notably, Adaptinol has received approval in Japan for the treatment of retinitis pigmentosa. According to the treatment guidelines authored by Takahashi Masahiro et al., Adaptinol is considered an oral carotenoid presumed to exert effects similar to lutein. It is commonly used to temporarily enhance the visual field and dark adaptation in individuals with retinitis pigmentosa.

To know more about retinitis pigmentosa treatment guidelines, visit @ Retinitis Pigmentosa Management 

Retinitis Pigmentosa Pipeline Therapies and Key Companies

  • Botaretigene sparoparvovec: Johnson & Johnson Innovative Medicine /MeiraGTx
  • AGTC-501: Beacon Therapeutics
  • MCO-010: Nanoscope Therapeutics
  • GS030: Gensight Biologics
  • 4D 125: 4D Molecular Therapeutics
  • CTx PDE6B: Coave Therapeutics
  • OCU 400: Ocugen
  • BS01: Bionic Sight
  • jCell: jCyte
  • EA-2353: Endogena Therapeutics
  • Ultevursen: ProQR Therapeutics
  • ADX 2191: Aldeyra Therapeutics

Learn more about the FDA-approved drugs for retinitis pigmentosa @ Drugs for Retinitis Pigmentosa Treatment 

Retinitis Pigmentosa Market Dynamics

The dynamics of the retinitis pigmentosa market are expected to change in the coming years. Gene therapy, available in the market, is utilized to address the effects of defective, disease-causing genes by employing engineered viruses, or viral vectors, to deliver a functional gene version into cells. The rising prevalence of retinitis pigmentosa worldwide has spurred pharmaceutical companies to explore this market, aiming for enhanced revenues through specific research and development strategies. Multiple therapeutic targets exist, with Spark Therapeutics, a key player in the retinitis pigmentosa market, acquiring RhoNova in 2016 for a potential gene therapy targeting rhodopsin-linked autosomal dominant retinitis pigmentosa, an inherited retinal disease leading to visual impairment and, in severe cases, blindness. 

Furthermore, many potential therapies are being investigated for the treatment of retinitis pigmentosa, and it is safe to predict that the treatment space will significantly impact the retinitis pigmentosa market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the retinitis pigmentosa market in the 7MM.

Moreover, retinitis pigmentosa treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the retinitis pigmentosa market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the retinitis pigmentosa market growth.

Retinitis Pigmentosa Market Report Metrics

Details

Study Period

2020–2034

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Retinitis Pigmentosa Market CAGR

16.8 %

Retinitis Pigmentosa Market Size in 2023

USD 500 Million

Key Retinitis Pigmentosa Companies

Johnson & Johnson Innovative Medicine, MeiraGTx, Beacon Therapeutics, Nanoscope Therapeutics, Gensight Biologics, 4D Molecular Therapeutics, Coave Therapeutics, Ocugen, Bionic Sight, jCyte, Endogena Therapeutics, ProQR Therapeutics, Aldeyra Therapeutics, and others

Key Pipeline Retinitis Pigmentosa Therapies

Botaretigene sparoparvovec, AGTC-501, MCO-010, GS030, 4D 125, CTx PDE6B, OCU 400, BS01, jCell, EA-2353, Ultevursen, ADX 2191, and others

Scope of the Retinitis Pigmentosa Market Report

  • Therapeutic Assessment: Retinitis Pigmentosa current marketed and emerging therapies
  • Retinitis Pigmentosa Market Dynamics: Key Market Forecast Assumptions of Emerging Retinitis Pigmentosa Drugs and Market Outlook
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Retinitis Pigmentosa Market Access and Reimbursement

Discover more about retinitis pigmentosa drugs in development @ Retinitis Pigmentosa Clinical Trials

Table of Contents

1

KEY INSIGHTS

2

REPORT INTRODUCTION

3

EXECUTIVE SUMMARY OF RETINOPATHY OF PREMATURITY

4

KEY EVENTS

5

EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY

6

RETINOPATHY OF PREMATURITY MARKET OVERVIEW AT A GLANCE

6.1

MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN THE 7MM IN 2019

6.2

MARKET SHARE (%) DISTRIBUTION BY THERAPIES IN THE 7MM IN 2032

7

DISEASE BACKGROUND AND OVERVIEW

7.1

INTRODUCTION

7.2

CAUSES

7.3

SIGN AND SYMPTOMS

7.4

PATHOPHYSIOLOGY

7.5

PATHOGENESIS

7.6

DIAGNOSIS

7.7

TREATMENT MANAGEMENT OF RETINOPATHY OF PREMATURITY

7.8

GUIDELINES FOR RETINOPATHY OF PREMATURITY

7.8.1

American Academy of Pediatrics (AAP): 2018

7.8.1.1

Screening Guidelines

7.8.1.2

Treatment Guidelines

7.8.2

Royal College of Pediatrics and Child Health (RCPCH): 2022

7.8.2.1

Screening Guidelines

7.8.2.2

Treatment Guidelines

7.8.3

Screening Guidelines in England, Germany, France, and Italy

7.8.4

Japanese Ophthalmological Society: 2020

7.8.4.1

Guidelines for Follow-up after Intravitreal Injection of Ranibizumab

8

EPIDEMIOLOGY AND PATIENT POPULATION OF THE 7MM

8.1

KEY FINDINGS

8.2

ASSUMPTIONS AND RATIONALE

8.3

TOTAL INCIDENT CASES OF RETINOPATHY OF PREMATURITY IN THE 7MM

8.4

UNITED STATES

8.4.1

Total Incident Cases of Preterm Infants by Birth Weight (≤1,500g) in the United States

8.4.2

Total Incident Cases of Retinopathy of Prematurity in the United States

8.4.3

Total Treated Cases of Retinopathy of Prematurity in the United States

8.5

EU4 AND THE UK

8.5.1

Total Incident Cases of Preterm Infants by Birth Weight (≤1,500g) in EU4 and the UK

8.5.2

Total Incident Cases of Retinopathy of Prematurity in EU4 and the UK

8.5.3

Total Treated Cases of Retinopathy of Prematurity in EU4 and the UK

8.6

JAPAN

8.6.1

Total Incident Cases of Preterm Infants by Birth Weight (≤1,500g) in Japan

8.6.2

Total Incident Cases of Retinopathy of Prematurity in Japan

8.6.3

Total Treated Cases of Retinopathy of Prematurity in Japan

9

PATIENT JOURNEY

10

MARKETED DRUGS

10.1

KEY COMPETITORS

10.2

LUCENTIS (RANIBIZUMAB): NOVARTIS

10.2.1

Product Description

10.2.2

Regulatory Milestones

10.2.3

Other Development Activities

10.2.4

Pivotal Clinical Trial

10.2.5

Product Profile

10.3

EYLEA (AFLIBERCEPT): REGENERON/BAYER

10.3.1

Product Description

10.3.2

Regulatory Milestones

10.3.3

Other Development Activities

10.3.4

Pivotal Clinical Trial

10.3.5

Product Profile

11

KEY COMPETITORS FOR PRE-CLINICAL ASSETS

12

RETINOPATHY OF PREMATURITY: 7MM ANALYSIS

12.1

KEY FINDINGS

12.2

KEY MARKET FORECAST ASSUMPTIONS

12.3

MARKET OUTLOOK

12.4

TOTAL MARKET SIZE OF RETINOPATHY OF PREMATURITY IN THE 7MM

12.5

UNITED STATES MARKET SIZE

12.5.1

Total Market Size of Retinopathy of Prematurity in the United States

12.5.2

Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in the United States

12.6

EU4 AND THE UK MARKET SIZE

12.6.1

Total Market Size of Retinopathy of Prematurity in EU4 and the UK

12.6.2

Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in EU4 and the UK

12.7

JAPAN MARKET SIZE

12.7.1

Total Market Size of Retinopathy of Prematurity in Japan

12.7.2

Market Size of Retinopathy of Prematurity by Current and Emerging Therapies in Japan

13

UNMET NEEDS

14

SWOT ANALYSIS

15

KOL VIEWS

16

MARKET ACCESS AND REIMBURSEMENT

16.1

UNITED STATES

16.1.1

Centre for Medicare & Medicaid Services (CMS)

16.2

EU4 AND THE UK

16.2.1

Germany

16.2.2

France

16.2.3

Italy

16.2.4

Spain

16.2.5

United Kingdom

16.3

JAPAN

16.3.1

MHLW

16.4

REIMBURSEMENT OF RETINOPATHY OF PREMATURITY

16.4.1

EYLEA (aflibercept): Regeneron Pharmaceuticals/Bayer

16.4.2

LUCENTIS (ranibizumab): Novartis

17

APPENDIX

17.1

BIBLIOGRAPHY

17.2

REPORT METHODOLOGY

18

DELVEINSIGHT CAPABILITIES

19

DISCLAIMER

Related Reports

Retinitis Pigmentosa Pipeline

Retinitis Pigmentosa Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key retinitis pigmentosa companies, including Acucela Inc, Allergan Plc, Amarantus Bioscience Holdings Inc, Amgen Inc, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical Inc, Astellas Pharma Inc, Caladrius Biosciences Inc, Dompe Farmaceutici SpA, GenSight Biologics SA, Grupo Ferrer Internacional SA, IDPharma Co Ltd, Janssen Pharmaceutical, MeiraGTx, Anabasis Pharma, Allegro Ophthalmics, Nacuity Pharmaceuticals, ReNeuron, jCyte, Editas Medicine, SanBio, NightstarTherapeutics, Biogen, OiDE OptoEye, among others.

Retinitis Pigmentosa Epidemiology Forecast

Retinitis Pigmentosa Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted retinitis pigmentosa epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

X-Linked Retinitis Pigmentosa Market

X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key X-linked retinitis pigmentosa companies including Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation, among others.

X-Linked Retinitis Pigmentosa Pipeline

X-Linked Retinitis Pigmentosa Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key X-linked retinitis pigmentosa companies, including Biogen, 4D Molecular therapeutics, Applied Genetics Technology Corporation,  among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

Modal title

Also from this source

Eosinophilic Esophagitis Market Set to Surge as New Research Unveils Breakthrough Treatments | DelveInsight

Eosinophilic Esophagitis Market Set to Surge as New Research Unveils Breakthrough Treatments | DelveInsight

Eosinophilic esophagitis (EoE) is a multifaceted disease marked by diverse clinical features, including variations in age of onset, symptoms, disease ...

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

Cushing's Disease Market Poised for Significant Growth Across the 7MM During the Study Period (2020-2034) with Rising Awareness and Diagnostic Improvements | DelveInsight

DelveInsight's Cushing's Disease Market Insights report includes a comprehensive understanding of current treatment practices, Cushing's disease...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.